|Day Low/High||251.78 / 253.62|
|52 Wk Low/High||223.02 / 338.51|
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving treatments to people affected by central nervous system diseases and injuries, today announced that Biogen (NASDAQ:BIIB)...
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Bernstein 33 rd Annual Strategic Decisions Conference.
Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals' Phase 3 candidate, CIRARA™ (intravenous glyburide).
Insiders at Twitter, Biogen and three other companies have been snapping up shares of their own stock lately.
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
Investors focus on a drug's efficacy and safety. Much less time is spent considering the importance of manufacturing, even though it is a vital step in the drug approval process.
Another big rally made for a day of milestones: the Dow and S&P 500 enjoyed their best back-to-back gains of the year, while the Nasdaq scored a new record.
Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.
A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.
Biogen's new spine disease drug outperformed expectations during its commercial debut.
Biogen adjusted profit rose in the first quarter on a small increase in total revenue. Sales of the biotech company's multiple sclerosis drugs remain flat.
Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.
Biogen Inc. (NASDAQ: BIIB) today reported first quarter 2017 financial results, including: Total revenues of $2.
U.S. stock futures rise and European shares are mostly higher as global markets rally in the wake of Emmanuel Macron's victory in the first round of France's presidential elections.
When Biogen reports first-quarter earnings Tuesday, investors will be looking to see if Spinraza sales match or exceed $16 million consensus.
Biogen (NASDAQ:BIIB) will present Phase 3 end of study SPINRAZA ® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor function in...
Biogen (NASDAQ: BIIB) announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA ® (dimethyl fumarate) and TYSABRI ® (natalizumab), early in the course...
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Biogen (NASDAQ: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a marketing authorization...
Biogen (NASDAQ: BIIB) will present data from its portfolio of treatments and investigational therapies for people with serious neurological and neurodegenerative diseases at the 69th annual meeting of the American...
Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.
Biogen (NASDAQ:BIIB) today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), from...
Investors have turned away from biotech at a time when the sector is normally humming with presentations of new clinical data at springtime medical meetings.
In the short term, all that matters in the market is what someone is willing to pay, says Jim Cramer.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.
Biogen (NASDAQ: BIIB) will present data from its Alzheimer's and Parkinson's disease programs at the 13 th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) in Vienna, Austria March 29 -...